TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update
Rhea-AI Summary
TG Therapeutics (NASDAQ: TGTX) will hold a conference call on Wednesday, May 6, 2026 at 8:30 AM ET to discuss first quarter 2026 financial results and provide a business outlook for the rest of 2026.
Michael S. Weiss, Chairman and CEO, will host. A live webcast and a 30-day audio replay will be available on the company's Investors & Media Events page. Financial results will be released in a press release prior to the call.
Positive
- None.
Negative
- None.
News Market Reaction – TGTX
In the Apr 30 session, TGTX gained 0.60%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | Earnings call scheduling | Neutral | +3.5% | Set date and time to discuss Q4 and full-year 2025 results and outlook. |
| Oct 31 | Earnings call scheduling | Neutral | +2.2% | Announced Q3 2025 results call with business outlook and 30‑day replay. |
| Jul 30 | Earnings call scheduling | Neutral | +2.7% | Scheduled Q2 2025 call outlining results and business update for investors. |
| Apr 30 | Earnings call scheduling | Neutral | +3.8% | Announced Q1 2025 call timing and access details with webcast and replay. |
| Feb 26 | Earnings call scheduling | Neutral | +0.5% | Outlined Q4 and full-year 2024 call format, logistics, and replay window. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Announcements scheduling TG Therapeutics’ earnings and business update calls have historically coincided with modestly positive one-day moves, suggesting investors often react constructively to upcoming financial disclosures.
Over the past five quarters, TG Therapeutics has repeatedly issued similar notices scheduling earnings and business update conference calls, typically a few days before results. These “conferences,earnings” releases led to one-day gains between 0.45% and 3.76%, with an average move of about 2.52%. Today’s first quarter 2026 call announcement follows the same template: Michael S. Weiss hosts, results arrive via press release before the call, and a 30‑day replay is offered to investors.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call to be Held Wednesday, May 6, 2026, at 8:30 am ET
NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Wednesday, May 6, 2026, at 8:30 AM ET to discuss results for the first quarter 2026 and to provide a business outlook for the remainder of 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
